SPOTLIGHT: Booming vaccine market swells Sanofi's revenue

A sign of the times? When Sanofi-Aventis presented its 2007 results earlier this week, it trumpeted the 14.5 percent sales growth in its vaccines group. That's more than double its pharma growth--and it's without Gardasil, because Sanofi doesn't consolidate its Merck joint venture revenues. Now, vaccines account for 10 percent of group revenues. As In Vivo notes, "Rarely have so many of Big Pharma's slides been devoted to this once-unfashionable category." Report